Epilepsy Foundation Vision

To create a world without epilepsy and lives free from seizures and side effects.

Our purpose is to develop an epilepsy research ecosystem that covers the entire spectrum of discovery - from the idea to market. We foster the development of new scientists and support research that leads to better treatments and care. We strive for excellence, innovation, and radical thinking to end epilepsy.

Working with regulators and industry to get therapies to the market faster with our Research Roundtable

Hosting the Pipeline Conference to showcase the epilepsy pipeline to funders & the community at large

Educating the community of new research developments through our new upcoming Hot Topics page & the Epilepsy Pipeline

"Since 2003, we have provided funding to half of the therapies in the epilepsy clinical pipeline.

Our Impact

In 2017, the Epilepsy Therapy Project is supporting the first genetic therapy (Ataluren) for epilepsy.

"Support from the Epilepsy Foundation has allowed the first trial of a genetic therapy in epilepsy."

— Orrin Devinsky, MD

In 2013, the Epilepsy Therapy Project supported the first Epidiolex® (CBD) trial by GW Pharma for Dravet and Lennox-Gastaut.

"The origin of the Epidiolex trial began with a pivotal meeting of researchers from across the US and representatives of the Epilepsy Foundation."

— Orrin Devinsky, MD

In 2011, the SharkTank award went to SAMiTM by HiPass Designs for developing a sleep activity monitor to detect abnormal movements in the night.

"Winning the first Epilepsy Foundation Shark Tank Competition in 2011 allowed me to transform SAMi from an expensive custom solution for us into a refined, much less costly tool for others."

— Charles W. Anderson, President HiPass Designs

In 2011 the Epilepsy Therapy Project supported the development of Visualase® by Medtronic. Visualase is an MRI-Guided Laser Ablation Technology for Minimally Invasive Neurosurgery to reduce the risk of open-brain surgery for people living with epilepsy.

"Aside from the funding, validation by ETP experts who vetted our project, and found it to be a worthwhile pursuit, has been a significant factor in our rapid progress and expansion into new centers."

In 2009 and 2011, the Epilepsy Therapy Project funded the development of SmartWatch by Smart Monitor. This was one of the first watches to fuse sensor, mobile, and cloud technologies with big-data analytics to create an ease of use monitoring and alert system device for people living with epilepsy.

In 2008, the Epilepsy Therapy Project supported the early clinical studies of Dr. Christopher De Giorgio at UCLA for testing the Monarch eTNS device, a new noninvasive nerve stimulation device, to stop seizures. Those studies paved the way for the Monarch eTNS device to obtain approval by the European Union. Currently, Monarch eTNS, by Neurosigma, is being reviewed by the FDA.

Support Us

We won't stop until there are no seizures and no side effects. Our purpose is to accelerate the development of therapies for people living with epilepsy.